Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series

Carlos Singer; Spiridon Papapetropoulos; Manuel A. Gonzalez; Eugene L. Roberts; Abraham Lieberman

doi:10.1002/mds.20471

Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series

Carlos Singer, Spiridon Papapetropoulos, Manuel A. Gonzalez, Eugene L. Roberts, Abraham Lieberman

Neurology

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

We report our experience with 7 consecutive patients with Parkinson's disease (PD) who received rimantadine (the α-methyl derivative of amantadine) in substitution of amantadine due to peripheral side effects (lower limb edema, livedo reticularis). Mean age was 67.3 ± 5.9 years, the mean disease duration was 13 ± 6.3 years, and mean Hoehn and Yahr stage was 2.2 ± 0.4. A total of 3 patients experienced marked improvement of edema, and 1 patient experienced marked improvement of livedo reticularis. Only 1 of the 7 patients reported significant loss of motor benefit when amantadine was replaced with rimantadine. Our results demonstrate that rimantadine may be considered as an alternative to amantadine in patients experiencing amantadine-induced peripheral side effects.

Original language	English (US)
Pages (from-to)	873-877
Number of pages	5
Journal	Movement Disorders
Volume	20
Issue number	7
DOIs	https://doi.org/10.1002/mds.20471
State	Published - Jul 1 2005

Keywords

Amantadine
Edema
Parkinson's disease
Rimantadine

ASJC Scopus subject areas

Clinical Neurology
Neuroscience(all)

Access to Document

10.1002/mds.20471

Cite this

@article{778f7e17e64c49b0978d7e64a843ed40,

title = "Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series",

abstract = "We report our experience with 7 consecutive patients with Parkinson's disease (PD) who received rimantadine (the α-methyl derivative of amantadine) in substitution of amantadine due to peripheral side effects (lower limb edema, livedo reticularis). Mean age was 67.3 ± 5.9 years, the mean disease duration was 13 ± 6.3 years, and mean Hoehn and Yahr stage was 2.2 ± 0.4. A total of 3 patients experienced marked improvement of edema, and 1 patient experienced marked improvement of livedo reticularis. Only 1 of the 7 patients reported significant loss of motor benefit when amantadine was replaced with rimantadine. Our results demonstrate that rimantadine may be considered as an alternative to amantadine in patients experiencing amantadine-induced peripheral side effects.",

keywords = "Amantadine, Edema, Parkinson's disease, Rimantadine",

author = "Carlos Singer and Spiridon Papapetropoulos and Gonzalez, {Manuel A.} and Roberts, {Eugene L.} and Abraham Lieberman",

year = "2005",

month = jul,

day = "1",

doi = "10.1002/mds.20471",

language = "English (US)",

volume = "20",

pages = "873--877",

journal = "Movement Disorders",

issn = "0885-3185",

publisher = "John Wiley and Sons Inc.",

number = "7",

}

TY - JOUR

T1 - Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine

T2 - Report of a case series

AU - Singer, Carlos

AU - Papapetropoulos, Spiridon

AU - Gonzalez, Manuel A.

AU - Roberts, Eugene L.

AU - Lieberman, Abraham

PY - 2005/7/1

Y1 - 2005/7/1

N2 - We report our experience with 7 consecutive patients with Parkinson's disease (PD) who received rimantadine (the α-methyl derivative of amantadine) in substitution of amantadine due to peripheral side effects (lower limb edema, livedo reticularis). Mean age was 67.3 ± 5.9 years, the mean disease duration was 13 ± 6.3 years, and mean Hoehn and Yahr stage was 2.2 ± 0.4. A total of 3 patients experienced marked improvement of edema, and 1 patient experienced marked improvement of livedo reticularis. Only 1 of the 7 patients reported significant loss of motor benefit when amantadine was replaced with rimantadine. Our results demonstrate that rimantadine may be considered as an alternative to amantadine in patients experiencing amantadine-induced peripheral side effects.

AB - We report our experience with 7 consecutive patients with Parkinson's disease (PD) who received rimantadine (the α-methyl derivative of amantadine) in substitution of amantadine due to peripheral side effects (lower limb edema, livedo reticularis). Mean age was 67.3 ± 5.9 years, the mean disease duration was 13 ± 6.3 years, and mean Hoehn and Yahr stage was 2.2 ± 0.4. A total of 3 patients experienced marked improvement of edema, and 1 patient experienced marked improvement of livedo reticularis. Only 1 of the 7 patients reported significant loss of motor benefit when amantadine was replaced with rimantadine. Our results demonstrate that rimantadine may be considered as an alternative to amantadine in patients experiencing amantadine-induced peripheral side effects.

KW - Amantadine

KW - Edema

KW - Parkinson's disease

KW - Rimantadine

UR - http://www.scopus.com/inward/record.url?scp=24144485398&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144485398&partnerID=8YFLogxK

U2 - 10.1002/mds.20471

DO - 10.1002/mds.20471

M3 - Article

C2 - 15809995

AN - SCOPUS:24144485398

VL - 20

SP - 873

EP - 877

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 7

ER -

Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: Report of a case series

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this